NEWSROOM

Press Releases by Agendia


News

Press Releases

New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrintยฎ Read More

MINDACT in the News

News, videos, social media and more about the recently released MINDACTย phase III, prospective randomized trial resultsย  The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD atย the American Association for Read More

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrintโ€™s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients [โ€ฆ]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go โ€œbeyond the mammogramโ€ in a portrait series illustrating people touched by breast cancer.